Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization

Clinical Infectious Diseases

Volumn 43, Issue 11, 2006, Pages 1387-1394

  Snape, Matthew D ^a   Kelly, Dominic F ^a   Salt, Penny ^a,b   Green, Sarah ^a   Snowden, Claire ^a,c   Diggle, Linda ^a   Borkowski, Astrid ^d   Yu, Ly Mee ^a   Moxon, E Richard ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d Novartis Vaccine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; IMMUNOGLOBULIN G; MENINGIVAC; MENINGOCOCCUS VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; HUMANS; IMMUNIZATION, SECONDARY; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; RANDOM ALLOCATION; TIME FACTORS;

EID: 33751555760     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508776     Document Type: Article

References (24)

1. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(Suppl 1):S58-67.
2. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5:21-30.
3. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
4. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002; 186:1353-7.
5. Richmond P, Goldblatt D, Fusco PC, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999; 18:641-6.
6. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005; 24:128-31.
7. Choo S, Zuckerman J, Goilav C, Hatzmann E, Everard J, Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomized observer-blind controlled trial. Vaccine 2000; 18:2686-92.
8. McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002; 21:747-53.
9. McVernon J, MacLennan J, Pollard AJ, et al. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr Infect Dis J 2003; 22:659-61.
10. Borrow R. Long term protection of children - what can we learn from the past [abstract 16]. In: Program and abstracts of the 23rd Annual European Society for Paediatric Infectious Diseases (Valencia, Spain). Geneva: European Society for Paediatric Infectious Diseases, 2005:16.
11. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-4.
12. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569-72.
13. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: 1. the role of humoral antibodies. J Exp Med 1969; 129:1307-26.
14. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003; 21:1094-8.
15. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000; 283:2795-801.
16. Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 2002; 185:397-400.
17. Weller S, Reynaud CA, Weill JC. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol 2005; 26:85-9.
18. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829-31.
19. Glode M, Robbins JB, Liu TY, et al. Cross antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis 1977; 135:94-102.
20. Joint Committee of Vaccination and Immunisation (JCVI). Proposed changes to the routine immunisation schedule. 2006. Available at: http: //www.advisorybodies.doh.gov.uk/jevi/childhoodimmunisationoc05.pdf. Accessed 15 May 2006.
21. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987; 99:591-601.
22. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:821-32.
23. Pichichero ME, Voloshen T, Passador S. Kinetics of booster responses to Hacmophilus influenzae type B conjugate after combined diphtheriatetanus- acelluar pertussis-Hacmophilus influenzae type b vaccination in infants. Pediatr Infect Dis J 1999; 18:1106-8.
24. Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 2004; 9:11-5.